C U R R I C U L U M V I T A E

Personal details

Last name:	Aziz
First names:	Nasir Ahmad
Titles:	MD, PhD
Nationality:	Dutch
Date of birth:	07 December 1981
Address (work):	German Centre for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Str. 27, 53127 Bonn, Germany
Tel (work):	(+49) 0228 4330 2954
E-mail (work):	ahmad.aziz@dzne.de

Current positions

2018-present	Consultant Neurologist/Clinical Epidemiologist, Department of Population Health Sciences, German Centre for Neurodegenerative Diseases (DZNE), Bonn, Germany
2017-2018	Consultant Neurologist/Senior Clinical Research Associate UCL Institute of Neurology, Huntington Disease Research Centre, London, United Kingdom
2016-2017	*Marie-Sklodowska Curie Research Fellow* at the UCL Institute of Neurology, Huntington Disease Research Centre, London, United Kingdom. I was part of the team conducting the first in human gene-silencing trial in patients with Huntington disease (https://clinicaltrials.gov/ct2/show/NCT02519036). I also worked on identifying the genetic determinants of brain integrity in Huntington disease patients and healthy individuals using a combination of functional and structural MRI techniques and advanced bioinformatics (with Prof. S.J. Tabrizi).
2016-2017	*Clinical Fellow* in movement, neurogenetic and neurodegenerative disorders (with Prof. S.J. Tabrizi and Prof. K.P. Bhatia) at the National Hospital for Neurology and Neurosurgery, Queen Square, London.
2014-2018	*Principal investigator* at the Dept. of Neurology of the Leiden University Medical Centre, Leiden, the Netherlands. My group consisted of one MD/PhD student, one technician and rotating medical and biomedical MSc students. Our work included the following: - I was the PI of several international large-scale genetic association studies in patients with Huntington, Parkinson and Alzheimer disease as well as healthy controls from the general population (> 20000 individuals) to assess the contribution of CAG repeat polymorphisms to clinical phenotype with a special focus on cognition, mood and body weight/metabolism. - Generation of neuronal iPS cells from fibroblast lines of patients with polyglutamine diseases (including Huntington disease and spinocerebellar ataxias type 1 and 3) and assessment of bio-energetics, mitochondrial function and gene regulation networks in these cells to find modifiers of disease phenotype/progression.
2015-2017	*Principal site investigator* of the international PRIDE-HD trial (https://clinicaltrials.gov/ct2/show/NCT02006472) and the Open PRIDE-HD study (https://clinicaltrials.gov/ct2/show/NCT02494778).

Preclinical and clinical training

2015-2016	Completed training as a Clinical Epidemiologist (with a focus on genetic epidemiology and bioinformatics) at the Department of Clinical Epidemiology (LUMC) ("Epidemioloog B")
2011-2016	Completed training in Clinical Neurology (including training in neurophysiology, neuroradiology and neurosurgery) at Leiden University Medical Centre (LUMC, Leiden) and MCH Westeinde (a large tertiary hospital in The Hague), The Netherlands
2010-2014	Post-doctoral fellow at the Dept. of Neurology (LUMC)
2006-2018	Extensive experience with research in human subjects according to Good Clinical Practice guidelines (various clinical studies in patients with Huntington disease, Parkinson disease, narcolepsy as well as healthy volunteers)
2006-2014	Extensive experience with a range of neuropathological techniques, including immunocytochemistry, *in situ* hybridization, Western blotting, quantitative real-time PCR, as well as analysis of RNA sequencing data.

Education

2017	Board certification as a Neurologist (30/09/2017) and Clinical Epidemiologist (03/05/2017) (LUMC)
2009-2011	MD degree *(with highest honours)*
2006-2009	PhD student at the Departments of Neurology and Endocrinology of the LUMC, and the Netherlands Institute for Neuroscience (Amsterdam, The Netherlands). Supervisors: Prof. R.A.C. Roos, Prof. H. Pijl and Prof. D.F. Swaab. PhD degree awarded on 31/03/2010 (*with highest honours*)
2002-2006	Master's degree in Medicine (Leiden University, The Netherlands), (*with highest honours*)
2001-2002	Baccalaureate in Medicine (Leiden University, the Netherlands), (*with highest honours*)
1996-2001	Pre-university education (Rijnlands Lyceum, Sassenheim, the Netherlands), (*with highest honours*)

Grants

2016	Alkemade-Keuls research fund for studying the genetic determinants of Parkinson disease (*principal investigator*; 11 k€)
2016	Marie-Sklodowska Curie Individual Fellowship award for studying the effects of repeat polymorphisms on brain structure and function using functional and structural MRI (*principal investigator*; 100 k€)
2014	VENI grant from the Netherlands Organization for Scientific Research for the project: *"Triplet repeat polymorphisms as modifiers of health and disease"* (*principal investigator*; 250 k€) (*the most prestigious grant for early-stage postdoctoral researchers in the Netherlands*)
2014	Seed fund from the European Huntington Disease Network for the project: *„CAG repeat length polymorphisms as modifiers of clinical phenotype: Huntington disease and the general population"* (*principal investigator*; 50 k€)

2008	Cure Huntington's Disease Initiative (CHDI, Inc.) grant for research on hypothalamic changes in Huntington disease (co-applicant; 200 k€)
2006	Mosaic grant from the Netherlands Organisation for Scientific Research for studying hypothalamic, endocrine and metabolic alterations in Huntington and Parkinson disease (*main applicant*; 180 k€)

Prizes and awards

2015	Young Talent Award of the Dutch Society for Neuroscience
2014	Public award for the best presentation during the multidisciplinary 'Science day' of the 'Rijnland Hospital' (Leiderdorp, The Netherlands)
2014	Public award for the best presentation during the 'Science day' of the Dept. of Neurology of LUMC (certificate of appreciation)
2013	Article on the 'P-index' (see list of publications) included in the book *"The best idea of 2013"*) (ISBN: 978-90-79051-09-0)
2011	Dr. I. Snapperprijs 2011
2011	ARIA Award 2011 of the ARIA Students' Association for the best Afghan student in the Netherlands
2011	Selected by the 'Royal Dutch Academy of Arts and Sciences' and the 'Scientific Review Panel of the Council for the Lindau Nobel Laureate Meetings' for attendance of the 2011 Lindau Nobel Laureate Meeting dedicated to Physiology or Medicine in Lindau, Germany
2009	World Congress on Huntington's Disease young investigator award
2008	European Huntington Disease Network Poster Award
2005	Selected for and participated in the Leiden University's Honours Program
2003-2006	Selected for and participated in the Excellent Student's Program of the Leiden University Medical Centre
2001	Best student award from the 'Rijnlands Lyceum' (the Netherlands)

Scientific responsibilities and memberships

2013-present	Member of the scientific expert panel on neurodegenerative diseases for the journal '*Neurodegenerative Disease Management'*
2011-present	Member of the '*Nederlandse Vereniging voor Neurologie'* (i.e. Dutch Neurological Association), *'Vereniging voor Epidemiologie'* (i.e. Dutch Epidemiological Association', *International Movement Disorders Society,* and '*Jonge gezondheidsraad (jongGR)*' (i.e. the young Health Council of the Netherlands)
2010-2014	Managing Editor of *Frontiers in Bioscience*, special issue on '*Huntington disease*'
2006-present	Member of the European Huntington Disease Network; member of the 'Biomarkers working group' and the 'Genetic Modifiers working group'

Acted as reviewer for the following organisations and journals

2014-present	Grant reviewer for the Netherlands Organisation for Scientific Research (NWO/ZonMW) Grant reviewer for the French Foundation pour la Recherche Medicinale
2008-present	Acted as a reviewer for a large number of international journals including *Acta Neurologica Scandinavica, Alzheimer's Disease and Associated Disorders, American Journal of Medical Genetics: Part A, Brain, Brain Pathology, Brain*

Research Bulletin, Behavioral and Brain Functions, Britisch Journal of Clinical Pharmacology, British Medical Journal (BMJ), Clinical Genetics, Clinical Medicine Insights: Psychiatry, Cytokine, European Journal of Endocrinology, European Journal of Neurology, Expert Opinion On Investigational Drugs, Frontiers in Bioscience, Journal of Huntington Disease, Journal of Neurological Sciences, International Journal of Psychogeriatrics, Molecular Psychiatry, Movement Disorders, Movement Disorders Clinical Practice, Neurobiology of Disease, Neurodegenerative Disease Management, Neurology, Neurosciences, Palliative Medicine, PeerJ, Psychoneuroendocrinology, Scientific Reports, Scientometrics, Translational medicine, Translational Psychiatry

Teaching experience

Acted as direct (co-)supervisor of:

2015-present	Sarah Gardiner, MD (PhD candidate) (main supervisor)
2015-2017	Emma Coppen, MD (PhD candidate) (co-supervisor)
2016	Aster Harder (medical and biomedical student) (main supervisor)
2015-2016	Geerte Stuitje (biomedical student) (main supervisor)
2015-2017	Merel Boogaard (technician) (main supervisor)
2015	Yvonne Campman (medical student) (main supervisor)
2011-2014	Anjani Banwarie (medical student) (main supervisor)
2009-2014	Daniël J. van Wamelen, MD (PhD candidate) (main supervisor)
2008-2014	Claire H.M. Donjacoure, MD (PhD candidate) (co-supervisor)
2008-2011	Ilona D. Coops (medical student) (main supervisor)
2009	Christa Bénit (medical student) (main supervisor)
2007-2009	A.W. Maurits van der Graaf (medical student) (main supervisor)
2006-2009	Galia V. Anguelova, MSc (medical student/PhD candidate) (main supervisor)

Involved as course lecturer/teacher in:

2018	Bonn International Graduate School Clinical and Population Sciences (BIGS-CPS) course “Epidemiology”
2016	Minor ‘Translational Neuroscience’ for MSc biomedical students and MD students at LUMC
2015-2016	Research Methodology for Neurology Residents (together with Prof. F.R. Rosendaal) at LUMC
2011-2016	Lectures on clinical neurology for MD students in the final stages of their traineeship (‘co-assistenten’) at LUMC.

Research expertise

I have undertaken research activities on a wide range of subjects with a primary focus on neurodegenerative disorders, especially Huntington disease (HD) and Parkinson disease (PD):

- Several neuropathological studies at the Netherlands Institute for Neuroscience (Amsterdam, together with Prof. Dick Swaab) aimed at evaluating the integrity of the hypothalamus in HD patients (applying various techniques including immunocytochemistry, *in situ* hybridization, Western blotting, quantitative PCR).
- Various clinical studies in HD patients assessing the extent of endocrine, metabolic, sleep and autonomic changes applying a wide range of techniques (e.g. deconvolution modelling of hormone release, calorimetry, insulin clamp, stable isotope techniques, EEG/polysomnography).
- Questionnaire studies in a relatively large group of HD patients to characterize the prevalence

and correlates of sleep and autonomic nervous system dysfunction.
- Large scale database studies (in collaboration with the European HD Network and European HD Initiative study) evaluating the effects of *HTT* CAG repeat size variation on HD phenotype.
- Combined laboratory and database study on the determinants of *HTT* CAG repeat instability in HD patients.
- Several clinical experiments in patients with PD evaluating endocrine and metabolic changes.
- Clinical investigations in patients with narcolepsy studying the effects of γ-hydroxybuteric acid on sleep characteristics, hormone secretion and systemic metabolism.
- Devised a novel mathematical algorithm for selecting the optimal deconvolution model for hormone/time-series.
- Bibliometrics: development of a new bibliometric index (i.e. 'profit-index') which estimates the contribution of others' to the work of a particular author (publication #41). Together with the Centre for Science and Technology Studies at Leiden University we are currently assessing whether it is possible to identify 'freeloaders' in biomedical research (publication #63).
- Development of a novel strategy to apply measures from information theory to infer causality from observational studies in epidemiology (publication #54).
- Development of a computer program to analyse the characteristics of movement disorders in clinical neurology.
- Skin biopsies from patients with polyglutamine diseases and conversion of fibroblast cell lines into neuronal induced pluripotent stem cells (iPSCs) and assessment of bio-energetics and mitochondrial function in these cell lines.
- Currently coordinating several international large-scale genetic association studies in patients with Huntington, Parkinson and Alzheimer disease as well as healthy controls from the general population (> 20000 individuals) in order to assess the contribution of DNA repeat polymorphisms to clinical phenotype with a special focus on body weight/metabolism, cognition and mood.

Other skills

Languages

Dutch (fluent), English (fluent), Persian/Farsi (native speaker), German (high school level; comparable to 'Goethe-Zertifikat B2' level), French (high school level), Hindi-Urdu (mediocre)

Computational skills

- Computer programming (including Visual Basic, Visual C++, HTML and Java)
- Statistical packages (including SAS, SPSS/PASW, STATA and R)
- Various other programs (including MATLAB, InDesign, Photoshop, Canvas)

Scientific presentations

Numerous presentations at many national and international meetings, including (most important ones):

- *World Congress on Huntington Disease 2007* (Dresden, Germany)
- *European Huntington's Disease Network Annual Meeting 2008* (Lisbon, Portugal) *(invited speaker)*
- *World Congress on Huntington Disease 2009* (Vancouver, Canada)
- *European Association for the Study of Diabetes 2009* (Vienna, Austria) *(invited speaker)*
- *Centre for Biomedical Genetics Meeting, Neurogenetics: from gene to therapy 2009* (Amsterdam, the Netherlands) *(invited speaker)*

- *LUMC's scientific advisory board meeting 2013 (invited speaker)*
- *Dutch Society of Neuroscience 2015 (invited speaker)*
- *Dutch Society of Human Genetics 2015 (invited speaker)*
- *European Huntington's Disease Network Annual Meeting 2016* (The Hague, The Netherlands)

Media reports/impact on society

Parts of my work have been discussed in several (inter)national and local media (below is a list of the most relevant articles):

- Dutch national newspapers: Volkskrant (3 April 2010), NRC Handelsblad (27-28 april 2013; 2 November 2013; 16 November 2013), NRC Handelsblad (5 January 2018)
- Dutch local newspapers/magazines: Leidsch Dagblad (30 March 2010, 29 July 2014), De Neuroloog (2010; 17(3):6), Mare (Leiden University's magazine, 21 September 2006; 23 May 2013), Cicero (LUMC's magazine, 19 April 2010, 22 August 2011), 'Raggae & Ratelslangen' (Leiden University Press, 2010)
- International media: American Academy of Neurology News (13 November 2009), European Huntington Disease Network newsletter (issues of March, September and October 2009 as well as March 2015), CNN, LA Times, Huffington Post, De Standaard, Nederlands Dagblad (March 2017, regarding publication #51)

Publications

Chronological order:

1. **Aziz NA**, Swaab DF, Pijl H, Roos RA. (2007). Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. *Rev Neurosci.*18(3-4):223-251. (review)

2. **Aziz NA**, Aziz MI. (2007). Losing weight by defecating at night. *Medical Hypotheses*. 67(4): 989. (letter)

3. Roos RA, **Aziz NA** (2007). Hypocretin-1 and secondary signs in Huntington's disease. *Parkinsonism Rel Disorders.* 13: 387-390. (original article)

4. **Aziz NA**, Fronczek R, Maat-Schieman MA, Unmehopa U, Roelandse F, Overeem S, van Duinen S, Lammers GJ, Swaab DF, Roos RA. (2008). Hypocretin and Melanin-Concentrating Hormone in Patients with Huntington Disease. *Brain Pathol.* 18(4): 474-483. (original article)

5. **Aziz NA**, Van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, EHDI Study Group; Roos RA (2008). Weight loss in Huntington's disease increases with higher CAG repeat number. *Neurology.* 71(19): 1506-1513. (original article)

6. **Aziz NA**, Van der Marck MA, Olde Rikkert MGM, Pijl H, Bloem BR, Roos RA (2008). "Gewichtsverlies bij neurodegeneratieve aandoeningen.". *Tijdschr Neurol Neurochir*. 109;5:192-9. (review)

7. **Aziz NA**, Van Belzen MJ, Roos RA (2008). Intergenerational CAG repeat instability is highly heritable in Huntington's disease. *J Med Genet*. 45: 766. (letter)

8. **Aziz NA**, Van der Marck MA, Olde Rikkert MGM, Pijl H, Bloem BR, Roos RA (2008). Weight loss in neurodegenerative disorders. *J Neurol*. 255(12):1872-80. (review)

9. **Aziz NA**, Roos RA (2009). Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The *Gene*PD study. *Mov Disord*. 24(8):1253. (letter)

10. **Aziz NA**, Pijl H, Frölich M, Van der Graaf AW, Roelfsema F, Roos RA (2009). Increased activity of the hypothalamic-pituitary-adrenal axis in early-stage Huntington's disease patients. *J Clinical Endocrinol Metab.* 94(4):1223-8. (original article)

11. **Aziz NA**, Van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, Roos RA (2009). Weight loss in Huntington's disease increases with higher CAG repeat number. *Neurology*. 73(7): 572. (original article)

12. **Aziz NA**, Roelfsema F, Frölich M, Roos RA, Pijl H (2009). A strategy for finding the optimal deconvolution estimates for hormone secretory kinetics using AutoDecon. *Anal. Biochem.* 391(1):69-71. (original article)

13. **Aziz NA**, Pijl H, Frölich M, Van der Graaf AW, Roelfsema F, Roos RA (2009). Leptin secretion rate increases with higher CAG repeat number in Huntington's disease patients. *Clin Endocrinol (Oxf).*73(2): 206-11. (original article)

14. **Aziz NA**, Pijl H, Frölich M, Schröder-van der Elst JP, van der Bent C, Roelfsema F, Roos RA. Delayed onset of the diurnal melatonin rise in patients with Huntington's disease (2009). *J Neurol. 256:1961–1965.* (original article)

15. **Aziz NA**, Jurgens CK, Landwehrmeyer GB on behalf of the EHDN Registry Study Group, Van Roon-Mom WM, Van Ommen GJ, Stijnen T, Roos RA (2009). Normal and mutant *HTT* interact to affect clinical severity and progression in Huntington's disease. *Neurology.* 73(16): 1280-5. (original article)

16. **Aziz NA**, Pijl H, Frölich M, Schröder-van der Elst JP, van der Bent C, Roelfsema F, Roos RA (2010). Growth hormone and ghrelin secretion are associated with clinical severity in Huntington's disease. *Eur J Neurol.* 17(2): 280-8. (original article)

17. **Aziz NA**, Anguelova GV, Marinus J, Van Dijk JG, Roos RA (2010). Autonomic symptoms in patients and premanifest mutation carriers of Huntington's disease. *Eur J Neurol.* 17(8): 1068-74. (original article)

18. **Aziz NA**, Pijl H, Frölich M, Snel M, Streefland T, Roelfsema F, Roos RA. Systemic energy homeostasis in Huntington's disease patients. *J Neurol Neurosurg Psychiatry.* 81(11):1233-7. (original article)

19. **Aziz NA**, Anguelova GV, Marinus J, Lammers GJ, Roos RA (2010). Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease. *Parkinsonism Rel Disorders.* 16(5): 345-50. (original article)

20. **Aziz NA**, Pijl H, Frölich M, Roelfsema F, Roos RA. Altered thyrotropic and lactotropic axes regulation in Huntington's disease (2010). *Clin Endocrinol (Oxf).* 73(4): 540-5. (original article)

21. **Aziz NA**, Van der Burg JM, Roos RA. High insulinlike growth factor I is associated with cognitive decline in Huntington disease (2011). *Neurology.* 76(7): 675-6. (letter)

22. **Aziz NA**, Pijl H, Frölich M, Roelfsema F, Roos RA (2011). Leptin, adiponectin and resistin secretion and diurnal rhythmicity are unaltered in Parkinson's disease. *Movement Disorders.* 26(4): 760-1. (original article)

23. Van Wamelen DJ, Shan L, **Aziz NA**, Anink JA, Bao AM, Roos RA, Swaab DF (2010). Functional increase of brain histaminergic signalling in Huntington's disease. *Brain Pathol.* 21(4): 419-27. (original article)

24. Donjacour CE, **Aziz NA**, Frölich M, Roelfsema F, Overeem S, Lammers GJ, Pijl H. Sodium oxybate increases prolactin secretion in narcolepsy patients and healthy controls (2011). *Eur J Endocrinol.* 164(3): 363-70. (original article)

25. Donjacour CE, **Aziz NA**, Frölich M, Roelfsema F, Overeem S, Lammers GJ, Pijl H (2011). The effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. *Am J Physiol Endocrinol Metab*. 300(6): E1069-75. (original article)

26. **Aziz NA**, Van Belzen MJ, Coops ID, Belfroid RD, Roos RA (2011). Parent-of-Origin Differences of Mutant *HTT* CAG Repeat Instability in Huntington's disease. *Eur J Med Genet*. 54(4): 413-8. (original article)

27. **Aziz NA**, Pijl H, Frölich M, Roelfsema F, Roos RA (2011). Diurnal secretion profiles of growth hormone, thyrotropin and prolactin in Parkinson's disease. *J Neuroendocrinol.* 23(6): 519-24. (original article)

28. Van der Burg JM, Winqvist A, **Aziz NA**, Maat-Schieman ML, Roos RA, Bates GP, Brundin P, Björkqvist M, Wierup N (2011). Gastrointestinal dysfunction contributes to weight loss in Huntington's disease mice. *Neurobiol. Dis.* 44(1): 1-8. (original article)

29. **Aziz NA**, Pijl H, Roos RA. Weight loss in obese older adults (2011). *N Engl J Med.* 364(25): 2467.

30. **Aziz NA**, Van Roon-Mom WM, Roos RA (2011). CAG repeat size in the normal *HTT* allele and age of onset in Huntington's disease. *Movement Disorders* 26(13):2450-1. (letter)

31. Donjacour CE, Pardi D, **Aziz NA**, Frölich M, Roelfsema F, Overeem S, Pijl H, Lammers GJ (2011). Ghrelin and leptin levels in human narcolepsy and in response to sodium oxybate. *J Clin Sleep Med.* 9(8):797-803. (original article)

32. Van Wamelen DJ, **Aziz NA**, Anink JA, Roos RA, Swaab DF (2012). Paraventricular Nucleus Neuropeptide Expression in Huntington's disease Patients. *Brain Pathol.* 22(5), 654-661. (original article)

33. Van Wamelen DJ, **Aziz NA**, Anink JA, Roos RA, Swaab DF (2012). Neuropeptide Alterations in the Infundibular Nucleus of Huntington's disease Patients. *J.Neuroendocrinol.* 25(2):198-205. (original article)

34. Van Wamelen DJ, **Aziz NA**, Anink JA, Steenhoven R, Roos RA, Swaab DF (2013). The suprachiasmatic nucleus is severely affected in Huntington's disease patients. *Sleep.* 36(1): 117-125. (original article)

35. Donjacour CE, Kalsbeek A, Overeem S, Lammers GJ, Bothorel B, Pijl H, **Aziz NA** (2012). Altered circadian rhythm of melatonin concentrations in hypocretin deficient men. *Chronobiol Int. 29(3):356-62.* (original article)

36. **Aziz NA**, Roos RA, Gusella JF, Lee JM, Macdonald ME (2012). CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. *Neurology. 79(9):952.* (letter)

37. **Aziz NA**, Roos RA (2013). Weight loss in Huntington's disease: characteristics, pathophysiology and clinical management. *Neurodegenerative Disease Management*. 3(3): 253-266. (original article)

38. Donjacour CE, Pardi D, **Aziz NA**, Frölich M, Roelfsema F, Overeem S, Pijl H, Lammers GJ (2013). Plasma Total Ghrelin and Leptin Levels in Human Narcolepsy and Matched Healthy Controls: Basal Concentrations and Response to Sodium Oxybate. *Journal of Clinical Sleep Medicine*. 15;9(8):797-803. (original article)

39. **Aziz NA**, Roos RA (2013). Characteristics, pathophysiology and clinical management of weight loss in Huntington's disease. *Neurodegenerative Disease Management.* 3(3): 253-266. (review)

40. Van Wamelen DJ, **Aziz NA**, Zhao J, Balesar R, Unmehopa U, Anink JA, Roos RA, Swaab DF (2013). Decreased hypothalamic prohormone convertase expression in Huntington's disease patients. *J Neuropathol Exp Neurol.* 72(12):1126-34. (original article)

41. **Aziz NA**, Rozing MP (2013). Profit (*p*) index: the degree to which authors benefit from co-authors. *Plos ONE.* 8(4): e59814. (original article) *This article was included in the book "The best idea of 2013" (ISBN: 978-90-79051-09-0) and kickstarted a national discussion on the use (and misuse of) bibliometic indices, including coverage by NRC Handelsblad (27-28 april 2013; 2 November 2013; 16 November 2013).*

42. Van Wamelen DJ, **Aziz NA**, Roos RA, Swaab DF (2014). Hypothalamic alterations in Huntington's disease patients: comparison with genetic rodent models. *J.Neuroendocrinol.* 26(11):761-75. (review)

43. Donjacour CE, **Aziz NA**, Overeem S, Kalsbeek A, Pijl H, Lammers GJ (2014). Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study. Sleep. 37(4):795-801. (original article)

44. Tannemaat MR, **Aziz NA** (2015). The prevalence of 'Clinical Neurophysiology' and related terms in the English literature: A specialty in transition. *Clin. Neurophysiol.* 126(8): 1459-61. (editorial)

45. **Aziz NA**, Tannemaat MR (2015). A microscope for subtle movements in clinical neurology. *Neurology.* 85(10):920. (Video NeuroImage)

46. Van der Burg JM, Pijl H, Campman YJ, Roos RA, **Aziz NA** (2015). Does midlife obesity really lower dementia risk? *Lancet Diabetes & Endocrinology* 3(7):499-500. (letter)

47. **Aziz NA**, Peeters-Scholte CM, de Bruine FT, Klumper FJ, Adama van Scheltema PN, Lopriore E, Steggerda SJ (2016). Fetal cerebellar hemorrhage, three cases with follow-up. *Ultrasound Obstet Gynecol.* 47(6): 785-6. (original article)

48. **Aziz NA**, Onkenhout W, Kerstens HJ, Roos RA (2015). Cystathionine Levels in Patients With Huntington Disease (2015). *Plos Curr.* 16(7). (original article)

49. Van Wamelen DJ, Roos RA, **Aziz NA** (2015). Managing sleep and circadian rhythm disturbances in Huntington disease (2015). *Neurodegenerative Disease Management.* 5(6): 549-59. (review)

50. Tannemaat MR, **Aziz NA** (2017). Creating dynamic virtual quarantines using "Pokémon Go" to limit infectious diseases spread. *Medical Hypotheses*. 99: 76-7. (letter)

51. Blauw LL[*], **Aziz NA**[*], Tannemaat MR, Blauw CA, De Craen AJ, Pijl H, Rensen PC (2017). Diabetes incidence and glucose intolerance prevalence increase with higher outdoor temperature. *BMJ Open Diabetes Research & Care.* 5: e000317. [*]*Joint first-author (This article received wide international media coverage, including CNN, LA Times, Huffington Post, 'De Standaard' and 'Nederlands Dagblad').* (original article)

52. Stuitje GA, Van Belzen MJ, Gardiner SL, Van Roon-Mom WM, Boogaard MW, REGISTRY Investigators of the European Huntington Disease Network, Tabrizi SJ, Roos RA, **Aziz NA** (2017). Age of onset in Huntington disease is influenced by CAG repeat variations in other polyglutamine disease-associated genes. *Brain. 140(7):e42. doi: 10.1093/brain/awx122.* (research letter)

53. Gardiner SL, Van Belzen MJ, Boogaard MW; Van Roon-Mom WM, Rozing MP, Van Hemert AM, Smit JH, Beekman AT, Van Grootheest G, Schoevers RA, Oude Voshaar RC, Comijs HC, Penninx BW, Van der Mast RC, Roos RA, **Aziz NA** (2017). Large normal-range *TBP* and *ATXN7* CAG repeat lengths are associated with increased lifetime risk of depression. *Translational Psychiatry. 7(6): e1143. doi: 10.1038/tp.2017.116.* (original article)

54. **Aziz NA** (2017). Transfer entropy as a tool for inferring causality from observational studies in epidemiology. *bioRxiv* https://doi.org/10.1101/149625 (original article, preprint)

55. Gardiner SL, Van Belzen MJ, Boogaard MW; Van Roon-Mom WM, Rozing MP, Van Hemert AM, Smit JH, Beekman AT, Van Grootheest G, Schoevers RA, Oude Voshaar RC, Roos RA, Comijs HC, Penninx BW, Van der Mast RC, **Aziz NA** (2017). Huntingtin gene repeat size variations affect risk of lifetime depression. *Translational Psychiatry. 7(12): e1143.* (original article)

56. Van der Burg JM, Gardiner SL, Ludolph AC, Landwehrmeyer GB, Roos RA, **Aziz NA** (2017). Body weight is a robust predictor of clinical progression in Huntington disease. *Annals of Neurology. 82(3):479-483.* (original article)

57. Aziz MH, Sideras K, **Aziz NA**, Haen R, Roos D, Saida L, Suker M, van der Harst E, Mieog JS, Bonsing BA, Klaver Y, Groot Koerkamp B, van Eijck CH (2017). The systemic immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels. *Annals of Surgery (accepted)* (original article)

58. Keo A, **Aziz NA**, Dzyubachyk O, Van der Grond J, Roon-Mom WM, Lelieveldt BF, Reinders MJ, Mahfouz A (2017). Co-expression patterns between *ATN1* and *ATXN2* coincide with brain regions affected in Huntington's disease. *Frontiers in Molecular Neuroscience.10:399.* (original article)

59. **Aziz NA**, Balint B (2017). The missing link in polyglutamine disorders. *Movement Disorders Clinical Practice. 5(1): 29-30.* (letter)

60. **Aziz NA**, Van der Burg JM, Tabrizi SJ, Landwehrmeyer GB. Overlap between age of onset and progression determinants in Huntington disease. *Neurology (accepted for publication)* (original article)

61. Gardiner SL, de Mutsert R, Trompet S, Boogaard MW, Van Dijk KW, Jukema JW, Slagboom PE, Roos RA, Pijl H, Rosendaal FR, **Aziz NA** (2018). Repeat length variations in polyglutamine disease-associated genes affect body mass index. *International Journal of Obesity* (*accepted for publication*) (original article)

Book chapters

1. **Aziz NA**, Vogel J (2005). "Reactieprocessen, aandacht en energetiek". In: *Cognitie, of hoe het brein werkt:* 81-93. Leiden University, Leiden, The Netherlands. (in Dutch)
2. Nijs S, **Aziz NA** (2005). "Een instinct voor taal?". In: *Cognitie, of hoe het brein werkt:* 107-118. Leiden University, Leiden, The Netherlands. (in Dutch)
3. **Aziz NA**, Van der Burg JM, Pijl H, Roos RA (2009). Huntington's disease and metabolic abnormalities: lessons from mice and men. In: *Treatment Strategies – EASD 2009 Review:* 32-39. The Cambridge Research Centre Ltd, United Kingdom.
4. **Aziz NA**, Roos RA (2010). Autonomic symptoms in Huntington's disease – current understanding and perspectives for the future. *European Neurological Review. 5(2): 46-8.*
5. Van der Burg JM, **Aziz NA**, Björkqvist M (2014). Peripheral pathology in Huntington's disease. In: *Huntington's disease (4th edition).* Editors: G. Bates, S. Tabrizi & Lesley Jones. Oxford University Press, New York.